Robert Suriano

List of Publications by Year
in descending order

23 papers	827 citations	686830 13 h-index	676716 22 g-index
23 all docs	23 docs citations	23 times ranked	1417 citing authors

#	Article	IF	Citations
1	Metastatic Phenotype Is Regulated by Estrogen in Thyroid Cells. Thyroid, 2010, 20, 33-41.	2.4	138
2	Endothelial progenitor cell biology in disease and tissue regeneration. Journal of Hematology and Oncology, 2011, 4, 24.	6.9	135
3	Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants. PLoS ONE, 2012, 7, e30839.	1.1	111
4	Estrogen Induced Metastatic Modulators MMP-2 and MMP-9 Are Targets of 3,3â€²-Diindolylmethane in Thyroid Cancer. PLoS ONE, 2011, 6, e15879.	1.1	68
5	Targeting the Immune System in Cancer. Current Pharmaceutical Biotechnology, 2009, 10, 166-184.	0.9	62
6	17Î²-Estradiol Mobilizes Bone Marrowâ€“Derived Endothelial Progenitor Cells to Tumors. Cancer Research, 2008, 68, 6038-6042.	0.4	46
7	3,3â€²-Diindolylmethane Modulates Estrogen Metabolism in Patients with Thyroid Proliferative Disease: A Pilot Study. Thyroid, 2011, 21, 299-304.	2.4	36
8	Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence. Molecular Cancer, 2012, 11, 80.	7.9	36
9	Estrogen-Mediated Angiogenesis in Thyroid Tumor Microenvironment Is Mediated Through VEGF Signaling Pathways. JAMA Otolaryngology, 2011, 137, 1146.	1.5	32
10	Estrogen activity as a preventive and therapeutic target in thyroid cancer. Biomedicine and Pharmacotherapy, 2012, 66, 151-158.	2.5	30
11	Differences in Glycosylation Patterns of Heat Shock Protein, gp96: Implications for Prostate Cancer Prevention. Cancer Research, 2005, 65, 6466-6475.	0.4	29
12	3,3'-Diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Oncology Reports, 2011, 25, 491-7.	1.2	20
13	Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma. Molecular and Clinical Oncology, 2013, 1, 466-472.	0.4	13
14	Molecular target based combinational therapeutic approaches in thyroid cancer. Journal of Translational Medicine, 2012, 10, 81.	1.8	10
15	Ex Vivo Derived Primary Melanoma Cells: Implications for Immunotherapeutic Vaccines. Journal of Cancer, 2013, 4, 371-382.	1.2	10
16	Sialic acid content of tissue-specific gp96 and its potential role in modulating gp96-macrophage interactions. Glycobiology, 2009, 19, 1427-1435.	1.3	9
17	Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. BMC Research Notes, 2014, 7, 187.	0.6	9
18	Ethanol Enhances Estrogen Mediated Angiogenesis in Breast Cancer. Journal of Cancer, 2018, 9, 3874-3885.	1.2	9

#	Article	IF	Citations
19	Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells. Oncotarget, 2016, 7, 8676-8687.	0.8	8
20	Estradiol-mediated tumor neo-vascularization. Oncology Letters, 2011, 2, 453-457.	0.8	7
21	PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. Journal of Cancer, 2015, 6, 1320-1330.	1.2	6
22	Identification of peptide mimotopes of gp96 using single-chain antibody library. Cell Stress and Chaperones, 2011, 16, 225-234.	1.2	3
23	Capridine-Î², a new class of chemotherapeutic agents for prostate cancer.. Journal of Clinical Oncology, 2014, 32, e16062-e16062.	0.8	0